Mumpsvax 4855716 215571542 2008-05-28T20:05:03Z DOI bot 6652755 Citation maintenance. You can [[WP:DOI|use this bot]] yourself! Please [[User:DOI_bot/bugs|report any bugs]]. '''Mumpsvax''' is a [[mumps vaccine]] made of mumps [[virus]]. Mumpsvax is a product of [[Merck & Co.]],Inc..<ref name="Merck_Mumpsvax_1999_pdf">{{cite web |url=http://www.merck.com/product/usa/pi_circulars/m/mumpsvax/mumpsvax_pi.pdf |title=MUMPSVAX (Mumps Virus Vaccine Live) Jeryl Lynn Strain |year=1990, 1999 |author=[[Merck & Co.|Merck Co.]] |publisher=Merck Co. }}</ref> The vaccine is a component of Merck's three-virus [[MMR vaccine]].<ref name="Merck_MMR2_1999_pdf">{{cite web |url=http://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf|title=M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live)|year=1990, 1999|author=[[Merck & Co.|Merck Co.]]|publisher=Merck Co.}}</ref> Mumpsvax is administered by a [[subcutaneous injection]] of live virus reconstituted from freeze-dried ([[lyophilization|lyophilized]]) vaccine.<ref name="Merck_Mumpsvax_1999_pdf"/> The dosage of the mumps vaccine component in MMR is the same as of Mumpsvax, "Each 0.5 mL dose contains not less than 20,000 TCID50 (tissue culture infectious doses) of mumps virus." The Merck product information recommends MMR as the secondary vaccination treatment with Mumpsvax. <ref name="Merck_Mumpsvax_1999_pdf"/> Mumpsvax is produced from the ''[[Jeryl Lynn Vaccine|Jeryl Lynn]]''<ref name="Jeryl_Lynn_1967_pdf">{{cite journal |url=http://pediatrics.aappublications.org/cgi/content/abstract/40/5/798 |title=Experiences with Jeryl Lynn strain live attenuated mumps virus vaccine in a pediatric outpatient clinic |year=1967 |author=Young ML, Dickstein B, Weibel RE, Stokes J Jr, Buynak EB, Hilleman MR. |journal=Pediatrics |publisher=American Academy of Pediatrics |pmid=6075651 }}</ref> strain of mumps virus developed by the late [[Maurice Hilleman]]. When his daughter Jeryl Lynn Hilleman contracted Mumps (in 1963) Dr. Hilleman cultured the vaccine strain from her throat. The mumps virus strains were developed in embryonic hens' eggs and chick embryo cell cultures. The resulting strains of virus were less well-suited for human cells, and are thus said to be ''attenuated''. They are sometimes referred to as ''neuroattenuated'' in the sense that these strains are less [[virulence|virulent]] to human [[neuron]]s than the wild strains.<ref name="WHO_Mumps_Vaccine">{{cite web|title=Immunization, Vaccines and Biologicals|url=http://www.who.int/vaccines/en/mumps.shtml#candidates|publisher=[[World Health Organization]]|year=2003}}</ref><ref name="">{{cite journal|url=http://www.pubmedcentral.gov/articlerender.fcgi?artid=229304|title=Changes in Mumps Virus Gene Sequence Associated with Variability in Neurovirulent Phenotype and the other such publications.|pmid=14557647}}</ref> The cells used in culture, virus stocks used, and animal fluids are all screened for extraneous material as part of the vaccine production. They are grown in [[Medium 199]] (a solution containing buffered salt, vitamins, amino acids, fetal bovine serum) with [[SPGA]](sucrose, phosphate, glutamate, [[human serum albumin]]) and [[neomycin]]. The human albumin processing uses the [[Cohn cold ethanol fractionation]] method.<ref name="Merck_Mumpsvax_1999_pdf"/> [[National Drug Code]]s for Mumpsvax are:<ref name="Merck_Mumpsvax_1999_pdf"/> {|border="1" cellspacing=0 cellpadding=2 |NDC 0006-4753-00 |A single-dose vial of lyophilized vaccine with a vial of [[diluent]]. |- |NDC 0006-4584-00 |A box of 10 single-dose vials of lyophylized vaccine with a box of 10 vials of diluent. |} ==References== {{reflist}} [[Category:Vaccines]]